Mukherjee P K
J Int Med Res. 1983;11(4):205-11. doi: 10.1177/030006058301100402.
Forty patients with primary chronic alcoholism took part in a randomized, double-blind, comparative group study of clobazam and chlordiazepoxide in the treatment of acute alcohol withdrawal. Assessments were carried out during an initial in-patient week followed by a week of out-patient assessments. Both benzodiazepines were shown to be highly effective when compared with baseline measurements. However, the Hamilton Anxiety Rating Scale showed clobazam to be more effective than chlordiazepoxide at both 7 days (p = 0.03) and 14 days (p less than 0.05). The clobazam group showed significant improvements compared with baseline for all four factors of the Leeds Sleep Evaluation Questionnaire, whereas the chlordiazepoxide group showed a significant improvement in only one factor. At the end of the in-patient week, clobazam showed a significant improvement (p less than 0.01) compared to chlordiazepoxide for the Linear Analogue Rating Scale of anxiety/tension. The 1,5 benzodiazepine clobazam has been shown to be a valuable addition to currently available regimens when used alone in the treatment of acute alcohol withdrawal, especially during the initial period where anxiety and insomnia related symptoms are at their peak.
40名原发性慢性酒精中毒患者参与了一项氯巴占与氯氮䓬治疗急性酒精戒断的随机、双盲、对照分组研究。评估在最初的住院一周期间进行,随后是一周的门诊评估。与基线测量值相比,两种苯二氮䓬类药物均显示出高效性。然而,汉密尔顿焦虑量表显示,在第7天(p = 0.03)和第14天(p < 0.05)时,氯巴占比氯氮䓬更有效。氯巴占组在利兹睡眠评估问卷的所有四个因素上与基线相比均有显著改善,而氯氮䓬组仅在一个因素上有显著改善。在住院一周结束时,对于焦虑/紧张的线性模拟评分量表,氯巴占与氯氮䓬相比有显著改善(p < 0.01)。1,5 - 苯二氮䓬类药物氯巴占已被证明,单独用于治疗急性酒精戒断时,尤其是在焦虑和失眠相关症状最为严重的初始阶段,是现有治疗方案中一个有价值的补充。